DUBLIN--(BUSINESS WIRE)--The "Thyroid Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Thyroid cancer - Pipeline Insight, 2021" report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid cancer.
Thyroid cancer Emerging Drugs Chapters
This segment of the Thyroid cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Thyroid cancer Emerging Drugs
Donafenib: Suzhou Zelgen Biopharmaceuticals
Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.
Ponatinib: Takeda
Ponatinib is an orally active, small-molecule multi-targeted tyrosine kinase inhibitor (TKI), being developed by Takeda, for the treatment of various cancer. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
Nivolumab: Bristol-Myers Squibb
Nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.
Thyroid cancer: Therapeutic Assessment
This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Thyroid cancer
There are approx. 35+ key companies which are developing the therapies for Thyroid cancer. The companies which have their Thyroid cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.
Phases
This report covers around 35+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Thyroid cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid cancer drugs.
Thyroid cancer Report Insights
- Thyroid cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Thyroid cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
- How many companies are developing Thyroid cancer drugs?
- How many Thyroid cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Thyroid cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Thyroid cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Suzhou Zelgen Biopharmaceuticals
- Jiangsu Chia-Tai Tianqing Pharmaceutical
- Takeda
- Bristol-Myers Squibb
- Genentech
- AffyImmune Therapeutics, Inc.
- Taizhou Hanzhong biomedical co. LTD
- NantCell, Inc.
- Bayer
- Merck Sharp & Dohme Corp.
- Pfizer
- MedImmune LLC
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Eisai Inc.
- cCAM Biotherapeutics
- Purple Biotech Ltd.
- Turning Point Therapeutics, Inc.
- Hoffmann-La Roche
- Bicara Therapeutics
- Novartis
- GlobeImmune
- GE Healthcare
- IBC Pharmaceuticals
- Debiopharm
- Blueprint Medicines
- Ono Pharmaceutical
- Array BioPharma
- Hutchison MediPharma
- Celldex Therapeutics Inc
- VBL Therapeutics
- Biovista
Key Products
- Donafenib
- Anlotinib
- Ponatinib
- Nivolumab
- Atezolizumab
- AIC100
- HX008
- GI-6207
- Ipilimumab
- Regorafenib
- MLN0128
- Pembrolizumab
- SU011248
- Durvalumab
- HA121-28
- Ifosfamide
- CM-24
- ETBX-011
- TPX-0046
- Entrectinib
- BCA101
- Spartalizumab
- GI 6207
- EMI 137
- Abemaciclib
- DEBIO 1124
- Gavreto
- Encorafenib
- Binimetinib
- Surufatinib
- CDX-3379
- VB-111
- BVA 701
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ca6p4y
